Anagrelide hydrochloride

ABT-199 (GDC-0199) is a BH3 mimetic that Bcl-2-selective inhibitor with Ki of &lt:0.01 nM. B-cell lymphoma/leukemia 2 (Bcl-2) is an anti-apoptotic protein that controls cell survival by binding the BH3 domains of pro-death BAD and BAK proteins and

ABT-199 (GDC-0199) is a BH3 mimetic that Bcl-2-selective inhibitor with Ki of &lt:0.01 nM. B-cell lymphoma/leukemia 2 (Bcl-2) is an anti-apoptotic protein that controls cell survival by binding the BH3 domains of pro-death BAD and BAK proteins and

ABT-199 (GDC-0199) is a BH3 mimetic that Bcl-2-selective inhibitor with Ki of &lt:0.01 nM. B-cell lymphoma/leukemia 2 (Bcl-2) is an anti-apoptotic protein that controls cell survival by binding the BH3 domains of pro-death BAD and BAK proteins and

ABT-199 (GDC-0199) is a BH3 mimetic that Bcl-2-selective inhibitor with Ki of &lt:0.01 nM. B-cell lymphoma/leukemia 2 (Bcl-2) is an anti-apoptotic protein that controls cell survival by binding the BH3 domains of pro-death BAD and BAK proteins and

ABT-199 (GDC-0199) is a BH3 mimetic that Bcl-2-selective inhibitor with Ki of &lt:0.01 nM. B-cell lymphoma/leukemia 2 (Bcl-2) is an anti-apoptotic protein that controls cell survival by binding the BH3 domains of pro-death BAD and BAK proteins and

ALBINE HYDROCHLORIDE

Product Describtion:Wnt agonist 1 (BML-284 HCL, AMBMP HCL) is a cell permeable Wnt signaling pathway activator, which induces β-catenin- and TCF-dependent transcriptional activity with EC50 of 0.7 μM.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

InformationAnagrelide HCl Anagrelide (BL-4162A) is a drug used for the treatment of essential thrombocytosis.In vitroAnagrelide is an oral imidazoquinazoline agent with an anti-cyclic AMP phosphodiesterase activity and inhibits platelet aggregation

Anagrelide HCl

Anagrelide HCl

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the